2CDA IN RELAPSING/REMITTING MULTIPLE SCLEROSIS

2CDA 在复发/缓解多发性硬化症中的作用

• 批准号: 6118102
• 负责人: JACK C SIPE
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118102
• 关键词: chlorodeoxyadenosine; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; magnetic resonance imaging; multiple sclerosis; nervous system disorder chemotherapy; relapse /recurrence

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS. We have completed treatment trials in chronic progressive MS (subproject #220) and have shown that cladribine, an immunosuppressive agent, retards the progression of the disease for two years or longer. A double-blind, placebo-controlled clinical trial of cladribine in relapsing-remitting MS has just been completed. The results indicate marked suppression of MRI-enhancing brain lesions in the cladribine treated group and significant reduction in both severity and frequency of clinical relapses. There was no significant toxicity or side effects of subcutaneously administered cladribine at the doses used in this study.

多发性硬化症（MS）是一种进行性神经系统疾病，可能有自身免疫基础。 我们一直在测试克拉屈滨（2-CdA）作为MS治疗的安全性和有效性。目前的其他治疗方法不令人满意，β干扰素和Copaxone对MS复发有部分作用。我们已经完成了慢性进展性MS的治疗试验（子项目#220），并表明克拉屈滨，一种免疫抑制剂，延缓疾病进展两年或更长时间。 克拉屈滨治疗复发缓解型MS的双盲、安慰剂对照临床试验刚刚完成。 结果表明，克拉屈滨治疗组MRI增强脑病变的显着抑制和临床复发的严重程度和频率显着降低。 在本研究中使用的剂量下皮下给予克拉屈滨没有显著的毒性或副作用。